Publications

Primary mediastinal large B-cell lymphoma (PML-BCL):long term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B  (2004)

Authors:
G. Todeschini; S. Secchi; E. Morra; U. Vitolo; E. Orlandi; F. Pasini; E. Gallo; A. Ambrosetti; C. Tecchio; C. Tarella; A. Gabbas; A. Gallamini; L. Garzantini; M. Pizzuti; G. Fioritoni; L. Gottin; G. Rossi; M. Lazzarino; F. Menestrina; M. Paulli; M. Palestro; Mg. Cabras; F. Di Vito; G. Pizzolo
Title:
Primary mediastinal large B-cell lymphoma (PML-BCL):long term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B
Year:
2004
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Format:
A Stampa
Referee:
Name of journal:
British Journal of Cancer
ISSN of journal:
0007-0920
N° Volume:
90
Page numbers:
372-376
Short description of contents:
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B (95). The two groups of patients were similar as regard to age, gender, presence of bulky mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk. Overall, 75.5% of patients in CR received IF-RT as consolidation. Complete remission was 51.1% in the CHOP group and 80% in MACOP-B/VACOP-B (P<0.001). Relapse occurred in 22.7% of CHOP- and in 9.2% of MACOP-B/VACOP-B-treated patients (n.s.). Event-free patients were 39.5% in CHOP and 75.7% in the MACOP-B/VACOP-B group (P<0.001). The addition of IF-RT as consolidation improved the outcome, irrespectively of the type of chemotherapy (P=0.04). At a multivariate analysis, achievement of CR (P<0.0001) and type of CT (MACOP-B/VACOP-B) retained the significance for OS (P=0.008) and EFS (P=0.03). In our experience, MACOP-B/VACOP-B appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on mediastinum further improves the outcome of CR patients.
Product ID:
23484
Handle IRIS:
11562/303421
Deposited On:
June 16, 2008
Last Modified:
May 22, 2017
Bibliographic citation:
G. Todeschini; S. Secchi; E. Morra; U. Vitolo; E. Orlandi; F. Pasini; E. Gallo; A. Ambrosetti; C. Tecchio; C. Tarella; A. Gabbas; A. Gallamini; L. Garzantini; M. Pizzuti; G. Fioritoni; L. Gottin; G. Rossi; M. Lazzarino; F. Menestrina; M. Paulli; M. Palestro; Mg. Cabras; F. Di Vito; G. Pizzolo, Primary mediastinal large B-cell lymphoma (PML-BCL):long term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B «British Journal of Cancer» , vol. 902004pp. 372-376

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back

Activities

Research facilities

Share